Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Feasability Study Using ch14.18/CHO Antibody and Subcutaneous Interleukin 2 After Haploidentical Stem Cell Transplantation in Children With Relapsed Neuroblastoma

NCT02258815 is registered in ClinicalTrials.gov with University Children's Hospital Tuebingen as lead sponsor.

NCT NCT02258815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02258815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Feasability Study Using ch14.18/CHO Antibody and Subcutaneous Interleukin 2 After Haploidentical Stem Cell Transplantation in Children With Relapsed Neuroblastoma
Lead sponsor
University Children's Hospital Tuebingen
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2010
Completion date
December 31, 2022
Enrollment
35 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma recurrent